Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

por Waissengrin, Barliz, Agbarya, Abed, Safadi, Esraa, Padova, Hagit, Wolf, Ido
Publicado 2021

Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients

por Ligumsky, Hagai, Safadi, Esraa, Etan, Tal, Vaknin, Noam, Waller, Manuel, Croll, Assaf, Nikolaevski-Berlin, Alla, Greenberg, Inbal, Halperin, Tami, Wasserman, Asaf, Galazan, Lior, Arber, Nadir, Wolf, Ido
Publicado 2021